FY2022 EPS Estimates for Humana Inc. Boosted by Analyst (NYSE:HUM)

Humana Inc. (NYSE:HUMGet Rating) – Analysts at Oppenheimer boosted their FY2022 EPS estimates for shares of Humana in a research note issued on Wednesday, April 27th. Oppenheimer analyst M. Wiederhorn now expects that the insurance provider will post earnings per share of $24.58 for the year, up from their previous estimate of $24.12. Oppenheimer also issued estimates for Humana’s FY2023 earnings at $27.30 EPS and FY2024 earnings at $30.38 EPS.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research upgraded Humana from a “sell” rating to a “hold” rating and set a $445.00 price objective on the stock in a research report on Friday, February 4th. Mizuho restated a “buy” rating and issued a $500.00 price objective on shares of Humana in a research report on Friday, January 7th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Humana from $418.00 to $435.00 in a research note on Thursday, February 3rd. Sanford C. Bernstein lowered their price target on shares of Humana from $470.00 to $431.00 in a research report on Tuesday, January 11th. Finally, Truist Financial raised their price target on Humana from $460.00 to $490.00 in a report on Thursday, April 7th. Seven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $487.41.

Shares of Humana stock opened at $458.99 on Friday. The stock has a fifty day moving average price of $440.23 and a 200-day moving average price of $434.99. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.62 and a quick ratio of 1.62. Humana has a 1 year low of $351.20 and a 1 year high of $475.44. The firm has a market cap of $58.17 billion, a PE ratio of 20.25, a P/E/G ratio of 1.38 and a beta of 0.94.

Humana (NYSE:HUMGet Rating) last posted its quarterly earnings data on Wednesday, April 27th. The insurance provider reported $8.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $6.79 by $1.25. The company had revenue of $23.97 billion during the quarter, compared to analysts’ expectations of $23.54 billion. Humana had a net margin of 3.53% and a return on equity of 17.39%. Humana’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same period in the prior year, the company posted $7.67 earnings per share.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Thursday, June 30th will be paid a dividend of $0.7875 per share. The ex-dividend date of this dividend is Wednesday, June 29th. This represents a $3.15 dividend on an annualized basis and a dividend yield of 0.69%. Humana’s payout ratio is 13.90%.

A number of hedge funds and other institutional investors have recently made changes to their positions in HUM. Spire Wealth Management purchased a new position in shares of Humana in the 4th quarter valued at approximately $30,000. Bell Investment Advisors Inc purchased a new stake in shares of Humana in the third quarter valued at $26,000. BerganKDV Wealth Management LLC increased its stake in shares of Humana by 885.7% during the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 62 shares during the last quarter. Riverview Trust Co acquired a new position in Humana during the first quarter worth approximately $32,000. Finally, Selective Wealth Management Inc. purchased a new position in shares of Humana in the 4th quarter worth $35,000. 92.96% of the stock is owned by institutional investors.

Humana Company Profile (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.